Core Viewpoint - Guilin Sanjin (002275) has confirmed that its products are sold in various overseas markets, including Eastern Europe, North America, Oceania, and Southeast Asia, but currently does not have sales in Japan and South Korea, nor any related foreign enterprise consultation or agency cooperation [1] Group 1 - The company has a presence in overseas markets such as Serbia, the United States, Canada, Australia, and most Southeast Asian countries [1] - There is currently no sales activity in Japan and South Korea [1] - The company has not engaged in any foreign enterprise consultation or agency cooperation for these regions [1]

证券日报网讯 桂林三金（002275）9月26日在互动平台回答投资者提问时表示，公司目前没有授权国外 企业生产相关产品，公司产品桂林西瓜霜（喷剂）具有清热解毒、消肿止痛之功效，用于急、慢性咽 炎，扁桃体炎，口腔炎，口腔溃疡等。是否可替代西药建议根据个人病情咨询医生或药师。 ...

格隆汇9月26日丨桂林三金(002275.SZ)在互动平台表示，公司目前没有授权国外企业生产相关产品，公 司产品桂林西瓜霜（喷剂）具有清热解毒、消肿止痛之功效，用于急、慢性咽炎，扁桃体炎，口腔炎， 口腔溃疡等。 ...

桂林三金（002275.SZ）9月26日在投资者互动平台表示，公司产品在海外很多市场都有销售，如东欧的 塞尔维亚、美洲的美国和加拿大、大洋洲的澳大利亚、东南亚地区大部分国家等。但是目前没有在日韩 地区销售，也没有相关外企咨询合作代理。 （记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：请问桂林三金西瓜霜含片是否在日韩有销售，是否有 相关国外企业咨询合作代理？ ...

Group 1 - The company is currently in the market development stage for its toothpaste business, specifically the Xigua Frost toothpaste under its subsidiary, Daily Chemical Health Products [2] - The expected sales for the toothpaste in 2024 are nearly 40 million yuan, which represents a small proportion of the company's overall revenue, indicating limited contribution to performance improvement [2] - The company plans to continue optimizing its product structure, accelerate the layout of distribution channels, actively expand e-commerce channels, and enhance the terminal brand image to achieve stable and continuous sales growth [2]

格隆汇9月23日丨桂林三金(002275.SZ)在投资者互动平台表示，西瓜霜牙膏为旗下子公司日化健康产 品，目前尚处于市场开拓阶段，根据2024年度销售情况，牙膏销售额近四千万元，占公司总体营收比例 较小，对业绩提升贡献有限，未来公司将继续优化产品结构，加快流通渠道布局，积极拓展电商渠道， 完善终端品牌形象，争取实现销量持续稳定增长。 ...

格隆汇9月23日丨桂林三金(002275.SZ)在投资者互动平台表示，西瓜霜牙膏为旗下子公司日化健康产 品，目前尚处于市场开拓阶段，根据2024年度销售情况，牙膏销售额近四千万元，占公司总体营收比例 较小，对业绩提升贡献有限，未来公司将继续优化产品结构，加快流通渠道布局，积极拓展电商渠道， 完善终端品牌形象，争取实现销量持续稳定增长。 ...

Company Overview - Guilin Sanjin Pharmaceutical Co., Ltd. is located in the Lingui District of Guilin City, Guangxi Zhuang Autonomous Region, established on February 23, 1994, and listed on July 10, 2009 [2] - The company specializes in the research, production, and sales of traditional Chinese medicine products, including throat and oral medications, anti-urinary tract infection drugs, and cardiovascular drugs, along with other natural medicines and biological preparations [2] - The main business revenue composition is as follows: Industrial 97.26%, Commodity circulation 2.37%, Other 0.38% [2] Stock Performance - As of September 23, the stock price of Guilin Sanjin fell by 2.11%, trading at 14.35 CNY per share, with a total market capitalization of 8.432 billion CNY [1] - Year-to-date, the stock price has decreased by 2.65%, with a 4.01% drop over the last five trading days and a 7.66% decline over the last 20 days [2] - The stock has appeared on the "Dragon and Tiger List" once this year, with the last appearance on January 7, where it recorded a net buy of -177.741 million CNY [2] Financial Performance - For the first half of 2025, Guilin Sanjin reported a revenue of 999.8 million CNY, a year-on-year decrease of 6.56%, and a net profit attributable to shareholders of 287 million CNY, down 4.70% year-on-year [3] - The company has distributed a total of 4.592 billion CNY in dividends since its A-share listing, with 1.175 billion CNY distributed over the last three years [4] Shareholder Information - As of September 10, the number of shareholders for Guilin Sanjin was 21,800, a decrease of 0.78% from the previous period, with an average of 25,628 circulating shares per shareholder, an increase of 0.78% [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 6.3037 million shares, an increase of 1.8371 million shares from the previous period [4] Market Position - Guilin Sanjin is classified under the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector [2] - The company is associated with several concept sectors, including anti-influenza, traditional Chinese medicine, small-cap stocks, innovative drugs, and margin financing [2]

Core Viewpoint - Guilin Sanjin experienced a slight decline in stock price and trading volume on September 17, with a focus on financing and margin trading activities, indicating a mixed sentiment among investors [1][2]. Financing Summary - On September 17, Guilin Sanjin had a financing buy-in amount of 5.23 million yuan, with a net financing purchase of 1.048 million yuan after 4.18 million yuan was repaid [1]. - The total financing and margin trading balance reached 13.8 million yuan, with financing balance accounting for 1.57% of the circulating market value, indicating a high level compared to the past year [1]. - The company’s financing balance of 1.37 billion yuan is above the 80th percentile of the past year, suggesting strong investor interest [1]. Margin Trading Summary - On the same day, Guilin Sanjin repaid 1,900 shares in margin trading and sold 200 shares, with the selling amount calculated at 2,972 yuan [1]. - The margin trading balance stood at 175,300 yuan, which is below the 50th percentile of the past year, indicating a lower level of margin trading activity [1]. Company Overview - Guilin Sanjin Pharmaceutical Co., Ltd. was established on February 23, 1994, and listed on July 10, 2009, focusing on the research, production, and sales of traditional Chinese medicine products related to throat and oral medications, urinary tract infection treatments, and cardiovascular drugs [1]. - The company’s main business revenue composition is 97.26% from industrial operations, 2.37% from commodity circulation, and 0.38% from other sources [1]. Financial Performance - For the first half of 2025, Guilin Sanjin reported an operating income of 998 million yuan, a year-on-year decrease of 6.56%, and a net profit attributable to shareholders of 287 million yuan, down 4.70% year-on-year [2]. - The company has cumulatively distributed 4.592 billion yuan in dividends since its A-share listing, with 1.175 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 10, the number of shareholders for Guilin Sanjin was 21,800, a decrease of 0.78% from the previous period, while the average circulating shares per person increased by 0.78% to 25,628 shares [2]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 6.3037 million shares, an increase of 1.8371 million shares from the previous period [3].

Group 1 - The company, Guilin Sanjin (002275), reported that as of September 10, 2025, the total number of shareholders is 21,813 [1]